{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:17:09Z","timestamp":1794835029804,"version":"4.9.1"},"reference-count":557,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.fjurol.2024.102735","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:59:15Z","timestamp":1732247955000},"page":"102735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Management of kidney cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Pierre","family":"Bigot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zine-Eddine","family":"Khene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albig\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Vergie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Doumerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Ferragu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Ingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Margue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idir","family":"Ouza\u00efd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pettenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rioux-Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Waeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2024.102735_bib1000","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.euf.2020.12.020","article-title":"A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome","volume":"8","author":"Huang","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10654-020-00650-3","article-title":"Global, regional and time-trend prevalence of central obesity: a systematic review and meta-analysis of 13.2 million subjects","volume":"35","author":"Wong","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1015","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/annonc\/mdw186","article-title":"International cancer seminars: a focus on kidney cancer","volume":"27","author":"Scelo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1020","first-page":"188","article-title":"Incidence of the main cancers in metropolitan France in 2023 and trends since 1990","volume":"12","author":"Lap\u00f4tre-Ledoux","year":"2023","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.fjurol.2024.102735_bib1025","unstructured":"Defossez G, Le Guyader-Peyro S, Uhry Z, Grosclaude P, Colonna M, Dantony E, et al. National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018 n.d."},{"key":"10.1016\/j.fjurol.2024.102735_bib1030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1040","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.euf.2017.01.006","article-title":"Variability of sex disparities in cancer incidence over 30 years: the striking case of kidney cancer","volume":"4","author":"Scelo","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary renal cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.fjurol.2024.102735_bib1050","doi-asserted-by":"crossref","first-page":"928619","DOI":"10.3389\/fonc.2022.928619","article-title":"Association between metabolic syndrome and risk of renal cell cancer: a meta-analysis","volume":"12","author":"Du","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2022.04.032","article-title":"Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies","volume":"82","author":"Graff","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1060","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1055-9965.EPI-23-0668","article-title":"Lifetime body weight trajectories and risk of renal cell cancer: a large U.S. prospective cohort study","volume":"32","author":"Deng","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.fjurol.2024.102735_bib1065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.urolonc.2018.12.008","article-title":"Systematic review of modifiable risk factors for kidney cancer","volume":"37","author":"Al-Bayati","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1070","first-page":"1317","article-title":"The relationship between blood pressure and risk of renal cell carcinoma","volume":"51","author":"Alcala","year":"2022","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1075","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.juro.2013.04.130","article-title":"Risk factors for renal cell carcinoma in the VITAL study","volume":"190","author":"Macleod","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2019.07.019","article-title":"Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis","volume":"142","author":"Liu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1085","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ijc.28144","article-title":"Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years","volume":"133","author":"Christensson","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1090","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/nep.13555","article-title":"Higher risk of malignant neoplasms in young adults with end-stage renal disease receiving haemodialysis: a nationwide population-based study","volume":"24","author":"Pan","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1095","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1681\/ASN.2013060604","article-title":"CKD and the risk of incident cancer","volume":"25","author":"Lowrance","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/21681805.2021.1900387","article-title":"Increased risk for renal cell carcinoma in end stage renal disease\u00a0\u2013\u00a0a population-based case-control study","volume":"55","author":"\u00c5kerlund","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1105","series-title":"Decree No. 2021-636 of 20 May 2021 revising and supplementing the tables of occupational diseases appended to Book IV of the Social Security Code","year":"2021"},{"key":"10.1016\/j.fjurol.2024.102735_bib1110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11157-012-9291-x","article-title":"Cometabolism of trichloroethylene: concepts, limitations and available strategies for sustained biodegradation","volume":"12","author":"Suttinun","year":"2013","journal-title":"Rev Environ Sci Biotechnol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1115","series-title":"Order of 4 May 1984 prohibiting the sale of trichlorethylene to minors and prohibiting preparations containing more than 5%","year":"1984"},{"key":"10.1016\/j.fjurol.2024.102735_bib1120","volume":"108","year":"2013"},{"key":"10.1016\/j.fjurol.2024.102735_bib1125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/jamainternmed.2016.1548","article-title":"Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults","volume":"176","author":"Moore","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1130","doi-asserted-by":"crossref","first-page":"17921","DOI":"10.1038\/srep17921","article-title":"Vitamin C intake and risk of renal cell carcinoma: a meta-analysis","volume":"5","author":"Jia","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib1135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MOU.0000000000000454","article-title":"Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition","volume":"28","author":"Tahbaz","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1140","doi-asserted-by":"crossref","first-page":"27892","DOI":"10.18632\/oncotarget.15841","article-title":"Consumption of fruits and vegetables and risk of renal cell carcinoma: a meta-analysis of observational studies","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.fjurol.2024.102735_bib1145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12916-021-02229-5","article-title":"The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies","volume":"20","author":"Liao","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41585-023-00781-8","article-title":"Effect of smoking, hypertension and lifestyle factors on kidney cancer\u00a0\u2013\u00a0perspectives for prevention and screening programmes","volume":"20","author":"Campi","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00345-022-03993-6","article-title":"Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group","volume":"41","author":"Diana","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euo.2020.12.011","article-title":"Novel liquid biomarkers and innovative imaging for kidney cancer diagnosis: what can be implemented in our practice today? A systematic review of the literature","volume":"4","author":"Campi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1165","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","article-title":"Epidemiology and screening for renal cancer","volume":"36","author":"Rossi","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1170","doi-asserted-by":"crossref","first-page":"e063018","DOI":"10.1136\/bmjopen-2022-063018","article-title":"The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer","volume":"12","author":"Usher-Smith","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.fjurol.2024.102735_bib1175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.euo.2023.02.012","article-title":"Estimating the effectiveness of kidney cancer screening within lung cancer screening programmes: a validation in UK biobank","volume":"6","author":"Harrison","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1180","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/cncr.34896","article-title":"Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance","volume":"129","author":"Daniels","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1185","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.euo.2019.11.002","article-title":"Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals","volume":"3","author":"Forde","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/21681805.2021.1900387","article-title":"Increased risk for renal cell carcinoma in end stage renal disease\u00a0\u2013\u00a0a population-based case-control study","volume":"55","author":"\u00c5kerlund","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.purol.2020.04.030","article-title":"[Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant: the French guidelines from CTAFU]","volume":"31","author":"Goujon","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(97)00506-2","article-title":"Increased incidence of serendipitously discovered renal cell carcinoma","volume":"51","author":"Jayson","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1205","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0044-101254","article-title":"The EFSUMB guidelines and recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in non-hepatic applications: update 2017 (short version)","volume":"39","author":"Sidhu","year":"2018","journal-title":"Ultraschall Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1210","doi-asserted-by":"crossref","first-page":"e0155857","DOI":"10.1371\/journal.pone.0155857","article-title":"The value of contrast-enhanced ultrasonography and contrast-enhanced CT in the diagnosis of malignant renal cystic lesions: a meta-analysis","volume":"11","author":"Lan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.fjurol.2024.102735_bib1215","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1007\/s00330-018-5504-1","article-title":"Evaluation of renal lesions using contrast-enhanced ultrasound (CEUS); a 10-year retrospective European single-centre analysis","volume":"28","author":"R\u00fcbenthaler","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1220","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00002018-199819040-00006","article-title":"Adverse effects of contrast media: incidence, prevention and management","volume":"19","author":"Thomsen","year":"1998","journal-title":"Drug Saf"},{"key":"10.1016\/j.fjurol.2024.102735_bib1225","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","article-title":"Post-contrast acute kidney injury\u00a0\u2013\u00a0part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1230","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1235","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00330-017-5023-5","article-title":"Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines","volume":"28","author":"Stacul","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiol.2522081180","article-title":"Segmental enhancement inversion at biphasic multidetector CT: characteristic finding of small renal oncocytoma","volume":"252","author":"Kim","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1245","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.juro.2008.10.040","article-title":"The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma","volume":"181","author":"Guzzo","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1148\/radiol.11111595","article-title":"The Bosniak renal cyst classification: 25 years later","volume":"262","author":"Bosniak","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1255","doi-asserted-by":"crossref","first-page":"W640","DOI":"10.2214\/AJR.14.14094","article-title":"Dual-energy MDCT for imaging the renal mass","volume":"204","author":"Mileto","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1260","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00261-019-01897-5","article-title":"Usefulness of rapid kV-switching dual energy CT in renal tumor characterization","volume":"44","author":"\u00c7aml\u0131da\u011f","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2214\/AJR.18.20990","article-title":"Diagnostic accuracy of attenuation difference and iodine concentration thresholds at rapid-kilovoltage-switching dual-energy CT for detection of enhancement in renal masses","volume":"213","author":"Sadoughi","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1270","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00261-017-1253-x","article-title":"Differentiation of renal cell carcinoma subtypes with different iodine quantification methods using single-phase contrast-enhanced dual-energy CT: areal vs. volumetric analyses","volume":"43","author":"Dai","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1275","doi-asserted-by":"crossref","first-page":"e230567","DOI":"10.1148\/radiol.230567","article-title":"Glomerular filtration rate measured based on iomeprol clearance assessed at CT urography in living kidney donor candidates","volume":"309","author":"Stehl\u00e9","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1280","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s00330-023-10145-w","article-title":"Applicability of Bosniak 2019 for renal mass classification on portal venous phase at the era of spectral CT imaging using rapid kV-switching dual-energy CT","volume":"34","author":"Reizine","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1285","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00261-024-04199-7","article-title":"Nomogram combining pre-operative clinical characteristics and spectral CT parameters for predicting the WHO\/ISUP pathological grading in clear cell renal cell carcinoma","volume":"49","author":"Zhang","year":"2024","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1290","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/02841851211002830","article-title":"Value of energy spectrum CT parameters in the differential diagnosis of high-grade clear cell renal cell carcinoma and type II papillary renal cell carcinoma","volume":"63","author":"Liang","year":"2022","journal-title":"Acta Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.crad.2014.10.001","article-title":"Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation","volume":"70","author":"Schieda","year":"2015","journal-title":"Clin Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1300","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1305","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00166.2016","article-title":"Pathophysiology of gadolinium-associated systemic fibrosis","volume":"311","author":"Wagner","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1310","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00330-015-3610-x","article-title":"Intracellular lipid in papillary renal cell carcinoma (pRCC): T2 weighted (T2W) MRI and pathologic correlation","volume":"25","author":"Schieda","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.sult.2016.08.009","article-title":"Multiparametric magnetic resonance imaging of solid renal tumors: a practical algorithm","volume":"38","author":"Cornelis","year":"2017","journal-title":"Semin Ultrasound CT MR"},{"key":"10.1016\/j.fjurol.2024.102735_bib1320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mric.2018.08.005","article-title":"Radiomics in kidney cancer: MR imaging","volume":"27","author":"de Leon","year":"2019","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib1325","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1148\/rg.2017170039","article-title":"Differentiation of solid renal tumors with multiparametric MR imaging","volume":"37","author":"Lopes Vendrami","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.fjurol.2024.102735_bib1330","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s00330-012-2758-x","article-title":"MR imaging of renal cortical tumours: qualitative and quantitative chemical shift imaging parameters","volume":"23","author":"Karlo","year":"2013","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2214\/AJR.16.16832","article-title":"Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas?","volume":"208","author":"Galmiche","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1340","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2214\/AJR.19.21907","article-title":"Apparent diffusion coefficient distinguishes malignancy in T1-hyperintense small renal masses","volume":"214","author":"Ludwig","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1345","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ucl.2018.03.003","article-title":"Diffusion-weighted genitourinary imaging","volume":"45","author":"Maurer","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib1350","doi-asserted-by":"crossref","first-page":"W152","DOI":"10.2214\/AJR.16.17649","article-title":"Utility of MRI to differentiate clear cell renal cell carcinoma adrenal metastases from adrenal adenomas","volume":"209","author":"Schieda","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1355","first-page":"69","article-title":"Comparison of MRI and CT for study of renal and perirenal masses","volume":"32","author":"Janus","year":"1991","journal-title":"Crit Rev Diagn Imaging"},{"key":"10.1016\/j.fjurol.2024.102735_bib1360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-010-0557-z","article-title":"Imaging of advanced renal cell carcinoma","volume":"28","author":"Mueller-Lisse","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1365","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1259\/0007-1285-64-764-683","article-title":"Magnetic resonance imaging in the staging of renal cell carcinoma","volume":"64","author":"Kabala","year":"1991","journal-title":"Br J Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1370","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.rct.0000146113.56194.6d","article-title":"Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation","volume":"29","author":"Hallscheidt","year":"2005","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.fjurol.2024.102735_bib1375","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s00261-018-1612-2","article-title":"Quantitative multiparametric MR analysis of small renal lesions: correlation with surgical pathology","volume":"43","author":"Yano","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2023.07.013","article-title":"The role of 99mTc-sestamibi single-photon emission computed tomography\/computed tomography in the diagnostic pathway for renal masses: a systematic review and meta-analysis","volume":"85","author":"Basile","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1385","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/JU.0000000000003557","article-title":"Clinical performance of technetium-99m-sestamibi SPECT\/CT imaging in differentiating oncocytic tumors from renal cell carcinoma in routine clinical practice","volume":"210","author":"Schober","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1390","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","author":"Lindenberg","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1395","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron emission tomography\/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1400","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"Minn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.fjurol.2024.102735_bib1405","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4554","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","author":"Shuch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1410","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/cancers13061348","article-title":"Radiomics in renal cell carcinoma\u00a0\u2013\u00a0a systematic review and meta-analysi","volume":"13","author":"M\u00fchlbauer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.fjurol.2024.102735_bib1415","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euf.2021.04.024","article-title":"Radiomics for renal cell carcinoma: predicting outcomes from immunotherapy and targeted therapies\u00a0\u2013\u00a0a narrative review","volume":"7","author":"Rallis","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1420","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1464-410X.2011.10452.x","article-title":"Utility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk: renal nephrometry scoring system","volume":"109","author":"Rosevear","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1425","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.eururo.2009.07.040","article-title":"Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery","volume":"56","author":"Ficarra","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1430","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.euf.2019.11.004","article-title":"Predictive value of nephrometry scores in nephron-sparing surgery: a systematic review and meta-analysis","volume":"6","author":"Veccia","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1435","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1440","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1445","first-page":"158","article-title":"Paraneoplastic and serologic syndromes of renal adenocarcinoma","volume":"7","author":"Sufrin","year":"1989","journal-title":"Semin Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1450","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.fjurol.2024.102735_bib1455","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","article-title":"Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study","volume":"7","author":"Huang","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1460","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u00a0\u2013\u00a0part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1465","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/j.clgc.2016.03.017","article-title":"Multilocular cystic renal cell neoplasm of low malignant potential: a series of 76 cases","volume":"14","author":"Li","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1470","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00428-018-2371-8","article-title":"Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum","volume":"473","author":"Tretiakova","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.fjurol.2024.102735_bib1475","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1480","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/PAS.0000000000001457","article-title":"Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study","volume":"44","author":"Tjota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1485","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41379-021-00737-6","article-title":"Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1490","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0000000000000838","article-title":"Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity","volume":"41","author":"Trpkov","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1495","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/PAS.0000000000000720","article-title":"TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity","volume":"40","author":"Argani","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1500","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/00000478-200212000-00003","article-title":"PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21)","volume":"26","author":"Argani","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1505","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PAS.0000000000001408","article-title":"Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum","volume":"44","author":"Xia","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1510","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/s41379-020-0578-0","article-title":"ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217","volume":"33","author":"Kuroda","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1515","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41379-019-0273-1","article-title":"Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases","volume":"32","author":"Jia","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1520","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.21037\/atm.2019.01.50","article-title":"Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement","volume":"7","author":"Swami","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2024.102735_bib1530","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1535","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/PAS.0b013e31829a85d0","article-title":"Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations","volume":"37","author":"Trpkov","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1540","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1545","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1097\/PAS.0b013e318299f12e","article-title":"Renal tumors: diagnostic and prognostic biomarkers","volume":"37","author":"Tan","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1550","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.annpat.2020.02.022","article-title":"[Hereditary kidney cancers: the pathologist's view in 2020]","volume":"40","author":"Verkarre","year":"2020","journal-title":"Ann Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1555","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.ctarc.2022.100640","article-title":"The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma","volume":"33","author":"Hahn","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.fjurol.2024.102735_bib1560","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.eururo.2021.01.042","article-title":"Sarcomatoid renal cell carcinoma: an immune checkpoint-responsive subset?","volume":"79","author":"Halabi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1565","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.urolonc.2017.12.012","article-title":"Sarcomatoid renal cell carcinoma: biology and treatment advances","volume":"36","author":"Mouallem","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1570","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1575","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","article-title":"Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy","volume":"69","author":"Marconi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1580","series-title":"Management of renal masses and localized renal cancer","author":"Pierorazio","year":"2016"},{"key":"10.1016\/j.fjurol.2024.102735_bib1585","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bju.13763","article-title":"Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis","volume":"119","author":"Patel","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1590","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00345-022-04261-3","article-title":"Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study","volume":"41","author":"Branger","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1595","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2022.04.009","article-title":"Benefit and harm of active surveillance for biopsy-proven renal oncocytoma: a systematic review and pooled analysis","volume":"41","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib1600","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bco2.141","article-title":"Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance","volume":"3","author":"Rodger","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.fjurol.2024.102735_bib1605","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.juro.2018.04.015","article-title":"Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?","volume":"200","author":"Richard","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1610","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bju.13630","article-title":"Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry","volume":"119","author":"Richard","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1615","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/JU.0000000000000113","article-title":"Risk factors for complications and nondiagnostic results following 1155 consecutive percutaneous core renal mass biopsies","volume":"201","author":"Posielski","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1620","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","article-title":"Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy","volume":"69","author":"Marconi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1625","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1111\/j.1464-410X.2012.11384.x","article-title":"Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention","volume":"111","author":"Menogue","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1630","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-021-01064-8","article-title":"Renal tumor biopsy: rationale to avoid surgery in small renal masses","volume":"22","author":"Amaral","year":"2021","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib1635","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2214\/AJR.23.29059","article-title":"Complications after renal mass biopsy: frequency, nature, timing, and associated characteristics","volume":"221","author":"Robert","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1640","first-page":"42","article-title":"Comprehensive assessment of the morbidity of renal mass biopsy: a population-based assessment of biopsy-related complications","volume":"15","author":"Garbens","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.fjurol.2024.102735_bib1645","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2018.12.011","article-title":"Tumour seeding in the tract of percutaneous renal tumour biopsy: a report on seven cases from a UK tertiary referral centre","volume":"75","author":"Macklin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1650","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clgc.2023.10.012","article-title":"Long-term follow-up in patients undergoing renal mass biopsy: seeding is not anecdotal","volume":"22","author":"Staehler","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1655","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.eururo.2015.04.004","article-title":"Renal tumor biopsy for small renal masses: a single-center 13-year experience","volume":"68","author":"Richard","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1660","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.clgc.2022.11.006","article-title":"Incidence of benign renal masses in a contemporary cohort of patients receiving partial nephrectomy for presumed renal cell carcinoma","volume":"21","author":"Vijay","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1665","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euros.2021.06.004","article-title":"Utilization of renal mass biopsy for T1 renal lesions across Michigan: results from MUSIC-KIDNEY. A statewide quality improvement collaborative","volume":"30","author":"Patel","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib1670","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000521153","article-title":"Ultrasound-guided renal mass biopsy and its clinical utility: a single-centre experience","volume":"106","author":"Jasinski","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1675","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/end.2021.0664","article-title":"Multidisciplinary approach and outcomes of pretreatment small (cT1a) renal mass biopsy: single-center experience","volume":"36","author":"Jiang","year":"2022","journal-title":"J Endourol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1680","first-page":"334","article-title":"Percutaneous biopsy of small renal mass: can diagnostic accuracy be affected by hospital volume?","volume":"74","author":"Ferrari","year":"2021","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1685","doi-asserted-by":"crossref","first-page":"735.e17","DOI":"10.1016\/j.urolonc.2021.05.024","article-title":"Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses?","volume":"39","author":"Okhunov","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1690","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2019.1703805","article-title":"Does renal mass biopsy influence multidisciplinary treatment recommendations?","volume":"54","author":"Lobo","year":"2020","journal-title":"Scand J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1695","doi-asserted-by":"crossref","first-page":"499.e15","DOI":"10.1016\/j.urolonc.2021.05.026","article-title":"The increasing use of renal tumor biopsy amongst Canadian urologists: when is biopsy most utilized?","volume":"39","author":"Couture","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1700","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2019.08.043","article-title":"Renal mass biopsy is associated with reduction in surgery for early-stage kidney cancer","volume":"135","author":"Patel","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1705","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ucl.2023.01.002","article-title":"The changing role of renal mass biopsy","volume":"50","author":"Ali","year":"2023","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib1710","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JU.0000000000003429","article-title":"Renal mass biopsy mandate is associated with change in treatment decisions","volume":"210","author":"Sinks","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1715","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.urology.2022.01.038","article-title":"Perspectives on the role of biopsy for management of T1 renal masses: survey results from two regional quality improvement collaboratives","volume":"165","author":"Prebay","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib1720","doi-asserted-by":"crossref","first-page":"79.e1","DOI":"10.1016\/j.urolonc.2020.10.015","article-title":"Utilization of renal mass biopsy in patients with localized renal cell carcinoma: a population-based study utilizing the National Cancer Database","volume":"39","author":"Patel","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1725","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.urolonc.2020.07.022","article-title":"Contemporary trends in percutaneous renal mass biopsy utilization in the United States","volume":"38","author":"Ozambela","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1730","first-page":"10285","article-title":"Analysis of guideline recommended use of renal mass biopsy and association with treatment","volume":"27","author":"Michel","year":"2020","journal-title":"Can J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1735","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.purol.2022.03.006","article-title":"Renal tumor biopsy does not increase the risk of surgical complications of minimally invasive partial nephrectomy","volume":"32","author":"Pasquier","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1740","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/end.2019.0297","article-title":"Utilization and operative influence of renal mass biopsy in the small renal mass: analysis from the Clinical Research Office of the Endourological Society Small Renal Mass registry","volume":"34","author":"Shahait","year":"2020","journal-title":"J Endourol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1745","first-page":"CD012045","article-title":"Partial nephrectomy versus radical nephrectomy for clinical localised renal masses","volume":"5","author":"Kunath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fjurol.2024.102735_bib1750","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2010.12.013","article-title":"A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"59","author":"Van Poppel","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1755","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/M17-0585","article-title":"Percutaneous ablation versus partial and radical nephrectomy for T1a renal cancer: a population-based analysis","volume":"169","author":"Talenfeld","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib1760","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eururo.2019.10.028","article-title":"Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the Eastern Cooperative Oncology Group\u00a0\u2013\u00a0American College of Radiology Imaging Network E2805 Trial Cohort","volume":"77","author":"Jamil","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1765","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2009.03.048","article-title":"Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery","volume":"57","author":"Bensalah","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1770","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.eururo.2010.02.019","article-title":"Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma","volume":"57","author":"Bernhard","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1775","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.juro.2016.05.078","article-title":"Treatment of patients with positive margins after partial nephrectomy","volume":"196","author":"Kim","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1780","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.juro.2017.09.072","article-title":"Local tumor bed recurrence following partial nephrectomy in patients with small renal masses","volume":"199","author":"Wood","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1785","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euo.2018.06.007","article-title":"Systematic review of the management of local kidney cancer relapse","volume":"1","author":"Kriegmair","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1790","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.euf.2021.02.007","article-title":"Percutaneous ablation versus surgical resection for local recurrence following partial nephrectomy for renal cell cancer: a propensity score analysis (REPART Study-UroCCR\u00a071)","volume":"8","author":"Brassier","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1795","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.eururo.2013.06.044","article-title":"Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904","volume":"65","author":"Scosyrev","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1800","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cncr.23218","article-title":"Renal and cardiovascular morbidity after partial or radical nephrectomy","volume":"112","author":"Miller","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib1805","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.09.027","article-title":"Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function","volume":"67","author":"Capitanio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1810","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.juro.2008.09.017","article-title":"Partial nephrectomy versus radical nephrectomy in patients with small renal tumors\u00a0\u2013\u00a0is there a difference in mortality and cardiovascular outcomes?","volume":"181","author":"Huang","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1815","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1464-410X.2009.08439.x","article-title":"Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma","volume":"104","author":"Gratzke","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1820","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/JU.0000000000000326","article-title":"Chronic kidney disease and kidney cancer surgery: new perspectives","volume":"203","author":"Huang","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1825","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2015.01.025","article-title":"Renal ischemia and function after partial nephrectomy: a collaborative review of the literature","volume":"68","author":"Volpe","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1830","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.juro.2015.01.093","article-title":"Decline in renal function after partial nephrectomy: etiology and prevention","volume":"193","author":"Mir","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1835","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eururo.2015.10.023","article-title":"Acute kidney injury after partial nephrectomy: role of parenchymal mass reduction and ischemia and impact on subsequent functional recovery","volume":"69","author":"Zhang","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1840","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.eururo.2018.10.005","article-title":"Ischemia techniques in nephron-sparing surgery: a systematic review and meta-analysis of surgical, oncological, and functional outcomes","volume":"75","author":"Greco","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1845","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.euf.2017.02.001","article-title":"Ischemia and functional recovery from partial nephrectomy: refined perspectives","volume":"4","author":"Dong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1850","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bju.16009","article-title":"Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time","volume":"132","author":"Cignoli","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1855","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bju.16250","article-title":"Off-clamp vs. on-clamp robot-assisted partial nephrectomy: a systematic review and meta-analysis","volume":"133","author":"Fong","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1860","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00345-020-03558-5","article-title":"Evaluation of oncological outcomes of robotic partial nephrectomy according to the type of hilar control approach (on-clamp vs. off-clamp), a multicentric study of the French network of research on kidney cancer-UROCCR 58-NCT03293563","volume":"41","author":"Mellouki","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1865","doi-asserted-by":"crossref","first-page":"5260131","DOI":"10.1155\/2022\/5260131","article-title":"The outcome of sutureless in partial nephrectomy: a systematic review and meta-analysis","volume":"2022","author":"Liu","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1870","doi-asserted-by":"crossref","first-page":"723","DOI":"10.23736\/S0393-2249.20.04005-9","article-title":"Functional and oncological outcomes of 3D clampless sutureless laparoscopic partial nephrectomy for renal tumors with low nephrometry score","volume":"72","author":"Introini","year":"2020","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1875","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.euo.2018.06.009","article-title":"Vascularized parenchymal mass preserved with partial nephrectomy: functional impact and predictive factors","volume":"2","author":"Wu","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1880","doi-asserted-by":"crossref","first-page":"661.e15","DOI":"10.1016\/j.urolonc.2017.07.007","article-title":"Simple tumor enucleation may not decrease oncologic outcomes for T1 renal cell carcinoma: a systematic review and meta-analysis","volume":"35","author":"Cao","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1885","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2023.03.008","article-title":"Resection techniques during robotic partial nephrectomy: a systematic review","volume":"52","author":"Bertolo","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib1890","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bju.13249","article-title":"Urinary fistula after robot-assisted partial nephrectomy: a multicentre analysis of 1791 patients","volume":"117","author":"Potretzke","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1895","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euf.2018.10.016","article-title":"What is better for predicting morbidity of robotic partial nephrectomy\u00a0\u2013\u00a0a score or your clinical judgement?","volume":"6","author":"Khene","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1900","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.eururo.2011.05.030","article-title":"Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy","volume":"60","author":"Simhan","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1905","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.euf.2021.04.017","article-title":"Predicting complications after robotic partial nephrectomy: back to simplicity","volume":"8","author":"Khene","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1910","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s00345-023-04491-z","article-title":"Late complications and 5 years outcomes of robotic partial nephrectomy in France: prospective assessment in the French Kidney Cancer Research Network (UroCCR 10)","volume":"41","author":"Margue","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1915","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bju.14250","article-title":"Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5\u00a0years\u2019 follow-up","volume":"122","author":"Chang","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1920","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euf.2019.10.013","article-title":"Perioperative outcomes of open, laparoscopic, and robotic partial nephrectomy: a prospective multicenter observational study (the RECORd 2 Project)","volume":"7","author":"Bravi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib1925","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2007.03.038","article-title":"Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors","volume":"178","author":"Gill","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1930","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JU.0000000000002695","article-title":"A prospective, randomized trial comparing the outcomes of open vs. laparoscopic partial nephrectomy","volume":"208","author":"Guglielmetti","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1935","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.suronc.2017.07.012","article-title":"Laparoscopic partial nephrectomy following tumor embolization in a hybrid room. Feasibility and clinical outcomes","volume":"26","author":"Panayotopoulos","year":"2017","journal-title":"Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1940","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1245\/s10434-016-5411-0","article-title":"Comparison of 1800 robotic and open partial nephrectomies for renal tumors","volume":"23","author":"Peyronnet","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1945","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1159\/000521881","article-title":"A systematic review and meta-analysis of comparison of outcomes of robot-assisted versus open partial nephrectomy in clinical T1 renal cell carcinoma patients","volume":"106","author":"Ni","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1950","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.urolonc.2011.08.004","article-title":"A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy","volume":"31","author":"Masson-Lecomte","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1955","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00345-020-03283-z","article-title":"Day-case robotic-assisted partial nephrectomy: feasibility and preliminary results of a prospective evaluation (UroCCR-25 AMBU-REIN study)","volume":"40","author":"Bernhard","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1960","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-022-04066-4","article-title":"Nurse-led coordinated surgical care pathways for cost optimization of robotic-assisted partial nephrectomy: medico-economic analysis of the UroCCR-25 AMBU-REIN study","volume":"41","author":"Bernhard","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1965","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eururo.2014.12.028","article-title":"Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis","volume":"67","author":"Choi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1970","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.eururo.2012.03.012","article-title":"Robotic versus laparoscopic partial nephrectomy for complex tumors: comparison of perioperative outcomes","volume":"61","author":"Long","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1975","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00345-021-03645-1","article-title":"3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51)","volume":"41","author":"Michiels","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1980","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1007\/s00464-020-07919-4","article-title":"Transperitoneal vs. retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (the RECORD 2 Project)","volume":"35","author":"Porpiglia","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.fjurol.2024.102735_bib1985","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00345-013-1213-1","article-title":"Is there a volume-outcome relationship for partial nephrectomy?","volume":"32","author":"Couapel","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib1990","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bju.14175","article-title":"Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study","volume":"121","author":"Peyronnet","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib1995","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/JU.0000000000000741","article-title":"Comparison of cancer specific outcomes following minimally invasive and open surgical resection of early stage kidney cancer from a National Cancer Registry","volume":"203","author":"Auffenberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2000","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2006.10.053","article-title":"Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison","volume":"177","author":"Hemal","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12957-023-02916-y","article-title":"Oncologic and perioperative outcomes of laparoscopic versus open radical nephrectomy for the treatment of renal tumor (>7cm): a systematic review and pooled analysis of comparative outcomes","volume":"21","author":"Wang","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.ju.0000145886.26719.73","article-title":"Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy","volume":"173","author":"Desai","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00345-008-0321-9","article-title":"A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma","volume":"27","author":"Hemal","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00330-018-5660-3","article-title":"Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis","volume":"29","author":"Uhlig","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2019.04.026","article-title":"Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses","volume":"76","author":"Andrews","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2030","doi-asserted-by":"crossref","first-page":"22.e1","DOI":"10.1016\/j.urolonc.2014.09.003","article-title":"Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses","volume":"33","author":"Larcher","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euo.2020.02.001","article-title":"Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel","volume":"3","author":"Abu-Ghanem","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2040","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1007\/s00330-023-09564-6","article-title":"A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study-UroCCR 80)","volume":"33","author":"Cazalas","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2045","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000000460","article-title":"Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer","volume":"202","author":"Pecoraro","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.11941116","article-title":"Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis","volume":"12","author":"Patel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2055","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00270-016-1417-z","article-title":"Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma","volume":"39","author":"Pantelidou","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.juro.2014.07.112","article-title":"Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes","volume":"193","author":"Chang","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2065","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1148\/radiol.2020190919","article-title":"Percutaneous microwave ablation versus laparoscopic partial nephrectomy for cT1a renal cell carcinoma: a propensity-matched cohort study of 1955 patients","volume":"294","author":"Yu","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2070","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2018180249","article-title":"Image-guided cryoablation for sporadic renal cell carcinoma: three- and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma","volume":"289","author":"Breen","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00270-014-0846-9","article-title":"Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours","volume":"37","author":"Katsanos","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00270-016-1531-y","article-title":"CIRSE guidelines on percutaneous ablation of small renal cell carcinoma","volume":"40","author":"Krokidis","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib2095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2100","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon.16.2","article-title":"Consensus statement from the International Radiosurgery Oncology Consortium for kidney for primary renal cell carcinoma","volume":"12","author":"Siva","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2110","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers13133129","article-title":"Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience","volume":"13","author":"Grelier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.fjurol.2024.102735_bib2115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clon.2022.06.007","article-title":"Stereotactic body radiotherapy for renal cell carcinoma: oncological and renal function outcomes","volume":"35","author":"Glicksman","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.fjurol.2024.102735_bib2120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2125","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/cancers12102763","article-title":"The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer","volume":"12","author":"Tetar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.fjurol.2024.102735_bib2130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2023.06.208","article-title":"TROG 15.03\/ANZUP international multicenter phase II trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II)","volume":"117","author":"Siva","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102735_bib2140","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.fjurol.2024.102660","article-title":"Stereotactic body radiation therapy for primary renal cell carcinoma: a review on behalf of the CC AFU","volume":"34","author":"Bentahila","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.euo.2018.05.001","article-title":"Role of active surveillance for localized small renal masses","volume":"1","author":"Mir","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2011.03.030","article-title":"Active surveillance of small renal masses: progression patterns of early stage kidney cancer","volume":"60","author":"Jewett","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.juro.2017.09.087","article-title":"Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry","volume":"199","author":"Uzosike","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bju.15435","article-title":"Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis","volume":"128","author":"Klatte","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2020.06.053","article-title":"Small renal mass surveillance: histology-specific growth rates in a biopsy-characterized cohort","volume":"78","author":"Finelli","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cncr.26369","article-title":"Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis","volume":"118","author":"Smaldone","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.eururo.2015.02.001","article-title":"Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry","volume":"68","author":"Pierorazio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2180","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/JU.0000000000001575","article-title":"Outcomes of active surveillance for young patients with small renal masses: prospective data from the DISSRM registry","volume":"205","author":"Metcalf","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bju.14490","article-title":"Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study","volume":"123","author":"Alam","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bju.14486","article-title":"Conditional survival of patients with small renal masses undergoing active surveillance","volume":"123","author":"Petros","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2195","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1464-410X.2012.11130.x","article-title":"Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy","volume":"110","author":"Patel","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2200","doi-asserted-by":"crossref","first-page":"603.e17","DOI":"10.1016\/j.urolonc.2020.02.015","article-title":"Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass","volume":"38","author":"Goldberg","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2205","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2013.01.034","article-title":"Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2210","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/j.juro.2013.02.185","article-title":"633 quality of life on active surveillance for a small renal masses versus immediate intervention: interim analysis of the dissrm (delayed intervention and surveillance for small renal masses) registry","volume":"189","author":"Pierorazio","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2215","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MOU.0000000000000081","article-title":"Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors","volume":"24","author":"Lee","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2220","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2016.08.060","article-title":"Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies","volume":"71","author":"Mir","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2225","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00345-013-1095-2","article-title":"Expanding utilization of robotic partial nephrectomy for clinical T1b and complex T1a renal masses","volume":"31","author":"Borghesi","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2230","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/iju.14664","article-title":"Partial versus radical nephrectomy in clinical T2 renal masses","volume":"28","author":"Klett","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2235","doi-asserted-by":"crossref","first-page":"680842","DOI":"10.3389\/fonc.2021.680842","article-title":"Partial nephrectomy versus radical nephrectomy for clinical T2 or higher stage renal tumors: a systematic review and meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2240","doi-asserted-by":"crossref","first-page":"e0196427","DOI":"10.1371\/journal.pone.0196427","article-title":"Survival outcomes in patients with large (\u22657cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: results of a multicenter cohort with long-term follow-up","volume":"13","author":"Janssen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.fjurol.2024.102735_bib2245","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/j.clgc.2020.05.002","article-title":"Oncologic and functional outcomes of radical and partial nephrectomy in pT3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis","volume":"18","author":"Patel","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bju.15959","article-title":"Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)","volume":"132","author":"Boulenger de Hauteclocque","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.juro.2017.03.012","article-title":"Partial nephrectomy is associated with higher risk of relapse compared with radical nephrectomy for clinical stage T1 renal cell carcinoma pathologically up staged to T3a","volume":"198","author":"Shah","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2260","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.21037\/tau-20-1262","article-title":"A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2265","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2270","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.urology.2015.02.067","article-title":"Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses\u22657\u00a0cm using the RENAL score","volume":"86","author":"Kopp","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2275","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bju.12580","article-title":"Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score","volume":"114","author":"Kopp","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2280","doi-asserted-by":"crossref","first-page":"12.e7","DOI":"10.1016\/j.urolonc.2017.09.005","article-title":"Incidence of T3a up-staging and survival after partial nephrectomy: size-stratified rates and implications for prognosis","volume":"36","author":"Srivastava","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00345-016-1849-8","article-title":"Robotic and open partial nephrectomy for complex renal tumors: a matched-pair comparison with a long-term follow-up","volume":"35","author":"Wang","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2290","doi-asserted-by":"crossref","first-page":"471.e1","DOI":"10.1016\/j.urolonc.2018.06.012","article-title":"Robotic versus open partial nephrectomy for highly complex renal masses: comparison of perioperative, functional, and oncological outcomes","volume":"36","author":"Garisto","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2295","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/iju.14469","article-title":"Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: a prospective multi-institutional study","volume":"28","author":"Hinata","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bju.15064","article-title":"Robotic partial nephrectomy vs. minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group","volume":"126","author":"Bradshaw","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2305","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s10147-022-02153-5","article-title":"Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma","volume":"27","author":"Dursun","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2310","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ejso.2015.02.009","article-title":"Evaluation of perioperative complications in open and laparoscopic surgery for renal cell cancer with tumor thrombus involvement using the Clavien-Dindo classification","volume":"41","author":"Ebbing","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2315","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.eururo.2012.07.028","article-title":"Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer","volume":"62","author":"MacLennan","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2320","doi-asserted-by":"crossref","first-page":"551052","DOI":"10.3389\/fonc.2020.551052","article-title":"Comparison of perioperative outcomes of robot-assisted vs. laparoscopic radical nephrectomy: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2490-14-75","article-title":"Robotic radical nephrectomy for renal cell carcinoma: a systematic review","volume":"14","author":"Asimakopoulos","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2330","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00345-019-02657-2","article-title":"Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group)","volume":"37","author":"Anele","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2335","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2017.14586","article-title":"Association of robotic-assisted vs. laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015","volume":"318","author":"Jeong","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.fjurol.2024.102735_bib2340","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.juro.2009.02.027","article-title":"Management of the adrenal gland during partial nephrectomy","volume":"181","author":"Lane","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2345","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2013.04.033","article-title":"Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma","volume":"64","author":"Bekema","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2350","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bju.12508","article-title":"Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC)","volume":"114","author":"Capitanio","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.urolonc.2018.03.006","article-title":"Role of lymph node dissection in renal cell cancer","volume":"37","author":"John","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2360","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.juro.2017.11.114","article-title":"Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis","volume":"199","author":"Gershman","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2365","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.juro.2010.12.053","article-title":"Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases","volume":"185","author":"Whitson","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.eururo.2008.09.052","article-title":"Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881","volume":"55","author":"Blom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2375","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1259\/bjr\/17514226","article-title":"Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma","volume":"82","author":"May","year":"2009","journal-title":"Br J Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2380","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1259\/bjr\/31311739","article-title":"Renal artery embolisation in the palliative treatment of renal carcinoma","volume":"80","author":"Maxwell","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2385","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.urology.2019.09.024","article-title":"Comparing outcomes for patients with clinical T1b renal cell carcinoma treated with either percutaneous microwave ablation or surgery","volume":"135","author":"Shapiro","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2390","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11604-018-0756-x","article-title":"Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study","volume":"36","author":"Hasegawa","year":"2018","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2395","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urolonc.2022.04.002","article-title":"Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: a systematic review and meta-analysis","volume":"40","author":"Yanagisawa","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2400","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/end.2009.0328","article-title":"Percutaneous cryoablation of renal masses>or=3cm: efficacy and safety in treatment of 108 patients","volume":"24","author":"Schmit","year":"2010","journal-title":"J Endourol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2405","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2214\/AJR.06.1152","article-title":"Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome","volume":"188","author":"Atwell","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2410","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for\u2265T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102735_bib2415","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euros.2022.03.005","article-title":"Clinical T1a renal cell carcinoma, not always a harmless disease\u00a0\u2013\u00a0a national register study","volume":"39","author":"Almdalal","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib2420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bju.15959","article-title":"Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)","volume":"132","author":"Boulenger de Hauteclocque","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2425","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.euf.2020.05.013","article-title":"Upstaging to pT3a in patients undergoing partial or radical nephrectomy for cT1 renal tumors: a systematic review and meta-analysis of outcomes and predictive factors","volume":"7","author":"Veccia","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib2430","doi-asserted-by":"crossref","first-page":"301.e11","DOI":"10.1016\/j.urolonc.2019.01.019","article-title":"The prognostic value of the site of invasion in T3aN0M0 clear cell renal cell carcinoma","volume":"37","author":"Guo","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2435","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2008.07.053","article-title":"Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma","volume":"55","author":"Wagner","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2440","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2010.10.001","article-title":"Prognostic impact of the 2009 UICC\/AJCC TNM staging system for renal cell carcinoma with venous extension","volume":"59","author":"Mart\u00ednez-Salamanca","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2445","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1464-410X.2008.07917.x","article-title":"Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma","volume":"102","author":"Zini","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2450","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/end.2016.0082","article-title":"Outcomes of minimal invasive vs. open radical nephrectomy for the treatment of locally advanced renal-cell carcinoma","volume":"30","author":"Bragayrac","year":"2016","journal-title":"J Endourol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2455","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clgc.2016.01.007","article-title":"Safety and feasibility of laparoscopic nephrectomy for big tumors (\u226510cm): a retrospective multicentric study","volume":"14","author":"Verhoest","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2460","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ucl.2020.04.004","article-title":"Minimally invasive surgery for patients with locally advanced and\/or metastatic renal cell carcinoma","volume":"47","author":"Becher","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib2465","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.eururo.2008.09.052","article-title":"Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881","volume":"55","author":"Blom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2470","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib2475","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2013.04.033","article-title":"Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma","volume":"64","author":"Bekema","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2480","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2016.09.019","article-title":"Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis","volume":"71","author":"Gershman","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2485","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-5347(17)39422-3","article-title":"Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases","volume":"144","author":"Studer","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2490","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.14127","article-title":"The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis","volume":"121","author":"Bhindi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2495","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","article-title":"Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma","volume":"80","author":"Correa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2500","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2010.09.034","article-title":"Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma","volume":"59","author":"Abel","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2505","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2510","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bju.14581","article-title":"Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study","volume":"123","author":"Lebacle","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2515","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3892\/ol.2024.14295","article-title":"Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.fjurol.2024.102735_bib2520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","article-title":"Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma","volume":"5","author":"Gorin","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2525","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2530","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2535","doi-asserted-by":"crossref","first-page":"104316","DOI":"10.1016\/j.critrevonc.2024.104316","article-title":"Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: a systematic review and meta-analysis","volume":"196","author":"Gu","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2540","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.urology.2014.10.006","article-title":"Stone size limits the use of hounsfield units for prediction of calcium oxalate stone composition","volume":"85","author":"Stewart","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2545","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ucl.2020.04.010","article-title":"Neoadjuvant therapy for locally advanced renal cell carcinoma","volume":"47","author":"Westerman","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib2550","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ucl.2023.01.011","article-title":"The promise of neoadjuvant and adjuvant therapies for renal cancer","volume":"50","author":"Leow","year":"2023","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.fjurol.2024.102735_bib2555","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.euo.2019.07.015","article-title":"Infiltrative renal masses: clinical significance and fidelity of documentation","volume":"4","author":"Tanaka","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2560","doi-asserted-by":"crossref","first-page":"237.e19","DOI":"10.1016\/j.urolonc.2015.11.020","article-title":"Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy","volume":"34","author":"Borregales","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2565","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1464-410X.2009.08484.x","article-title":"Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma)","volume":"104","author":"Capitanio","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2570","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.22629","article-title":"Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management","volume":"109","author":"Margulis","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2575","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.purol.2022.07.146","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0update 2022\u20132024: management of kidney cancer","volume":"32","author":"Bigot","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2580","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.urolonc.2011.12.006","article-title":"Natural history of untreated renal cell carcinoma with venous tumor thrombus","volume":"31","author":"Reese","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2585","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2011.02.032","article-title":"The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus","volume":"59","author":"Cost","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2590","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2595","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00345-014-1276-7","article-title":"Clinical management of renal cell carcinoma with venous tumor thrombus","volume":"32","author":"Agochukwu","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2600","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bju.13005","article-title":"Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus","volume":"116","author":"Psutka","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2605","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0022-5347(17)32288-7","article-title":"Preoperative computerized tomography detection of extensive invasion of the inferior vena cava by renal cell carcinoma: possible indication for resection with partial cardiopulmonary bypass and patch grafting","volume":"152","author":"Gohji","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2610","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.crad.2023.02.022","article-title":"Systematic review and meta-analysis of preoperative imaging prediction of renal cell carcinoma tumour thrombus inferior vena cava wall invasion","volume":"78","author":"Smith","year":"2023","journal-title":"Clin Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2615","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1464-410X.2005.05617.x","article-title":"Multidetector computed tomography vs. magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review","volume":"96","author":"Lawrentschuk","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2620","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/0970-1591.85439","article-title":"Budd-Chiari syndrome in urology: impact on nephrectomy for advanced renal cell carcinoma","volume":"27","author":"Shirodkar","year":"2011","journal-title":"Indian J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2625","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/JU.0000000000002829","article-title":"A decade of robotic-assisted radical nephrectomy with inferior vena cava thrombectomy: a systematic review and meta-analysis of perioperative outcomes","volume":"208","author":"Garg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2630","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.eururo.2020.03.020","article-title":"Robot-assisted cavectomy versus thrombectomy for level II inferior vena cava thrombus: decision-making scheme and multi-institutional analysis","volume":"78","author":"Shi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2635","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.euf.2017.01.001","article-title":"Robotic surgery for renal cell carcinoma with vena caval tumor thrombus","volume":"2","author":"Abaza","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib2640","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.juro.2015.03.119","article-title":"Robotic level III inferior vena cava tumor thrombectomy: initial series","volume":"194","author":"Gill","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2645","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-021-03640-6","article-title":"Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (UroCCR-56 study)","volume":"41","author":"Baboudjian","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2650","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib2655","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2660","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.euros.2024.02.015","article-title":"The impact of histological variants on oncological outcomes after surgical resection of a nonmetastatic renal cell carcinoma with tumor thrombus: a multi-institutional study","volume":"62","author":"Fleury","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib2665","doi-asserted-by":"crossref","first-page":"e0131290","DOI":"10.1371\/journal.pone.0131290","article-title":"Safety and efficacy of thermal ablation for small renal masses in solitary kidney: evidence from meta-analysis of comparative studies","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.fjurol.2024.102735_bib2670","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00345-016-1913-4","article-title":"Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting","volume":"35","author":"Long","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2675","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00345-022-04026-y","article-title":"Partial nephrectomy in solitary kidneys: comparison between open surgery and robotic-assisted laparoscopy on perioperative and functional outcomes (UroCCR-54 study)","volume":"41","author":"Benichou","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2680","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bju.15043","article-title":"Selective clamping during robot-assisted partial nephrectomy in patients with a solitary kidney: is it safe and does it help?","volume":"125","author":"Badani","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2685","doi-asserted-by":"crossref","first-page":"32.e17","DOI":"10.1016\/j.urolonc.2023.12.004","article-title":"Functional recovery after partial nephrectomy in a solitary kidney","volume":"42","author":"Attawettayanon","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2690","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2010.05.048","article-title":"Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney","volume":"58","author":"Thompson","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2695","first-page":"739","article-title":"On-clamp versus purely off-clamp robot-assisted partial nephrectomy in solitary kidneys: comparison of perioperative outcomes and chronic kidney disease progression at two high-volume centers","volume":"73","author":"Anceschi","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2700","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.3390\/cancers14184431","article-title":"On-clamp vs. off-clamp robot-assisted partial nephrectomy for cT2 renal tumors: retrospective propensity-score-matched multicenter outcome analysis","volume":"14","author":"Brassetti","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.fjurol.2024.102735_bib2705","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.purol.2020.04.029","article-title":"[Renal cell carcinoma of the kidney transplant: the French guidelines from CTAFU]","volume":"31","author":"Tillou","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2710","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/ajt.14366","article-title":"Solid renal masses in transplanted allograft kidneys: a closer look at the epidemiology and management","volume":"17","author":"Griffith","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.fjurol.2024.102735_bib2715","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00345-023-04495-9","article-title":"Renal cell carcinoma in kidney transplant recipients: incidence, trends, clinical management & outcomes","volume":"41","author":"Minkovich","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2720","doi-asserted-by":"crossref","first-page":"E570","DOI":"10.1111\/j.1464-410X.2012.11273.x","article-title":"Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?","volume":"110","author":"Gigante","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2725","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.purol.2020.04.030","article-title":"[Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant: the French guidelines from CTAFU]","volume":"31","author":"Goujon","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2730","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1016\/j.transproceed.2008.08.135","article-title":"Tumours in end-stage kidney","volume":"40","author":"Hora","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.fjurol.2024.102735_bib2735","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/nep.13555","article-title":"Higher risk of malignant neoplasms in young adults with end-stage renal disease receiving haemodialysis: a nationwide population-based study","volume":"24","author":"Pan","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.fjurol.2024.102735_bib2740","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1111\/j.1600-6143.2012.04248.x","article-title":"De novo kidney graft tumors: results from a multicentric retrospective national study","volume":"12","author":"Tillou","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.fjurol.2024.102735_bib2745","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s11255-020-02422-0","article-title":"De novo renal carcinoma arising in non-functional kidney graft: a national retrospective study","volume":"52","author":"Vaudreuil","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2750","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1111\/ctr.12088","article-title":"Treatment options for renal cell carcinoma in renal allografts: a case series from a single institution","volume":"27","author":"Swords","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.fjurol.2024.102735_bib2755","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.2011.10315.x","article-title":"Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort","volume":"109","author":"Ploussard","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2760","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000346624","article-title":"The high rate of de novo graft carcinomas in renal transplant recipients","volume":"37","author":"Viart","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2765","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/TP.0000000000003762","article-title":"Renal cell carcinoma and kidney transplantation: a narrative review","volume":"106","author":"Dahle","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.fjurol.2024.102735_bib2770","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/ajt.15151","article-title":"Robot-assisted laparoscopic partial nephrectomy with renal artery clamping using an endovascular balloon catheter for an allograft kidney tumor: a new perspective to manage renal vascular control?","volume":"19","author":"Laclergerie","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.fjurol.2024.102735_bib2775","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/00007890-200012150-00018","article-title":"Development of renal cell carcinoma in living donor kidney grafts","volume":"70","author":"Tyd\u00e9n","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.fjurol.2024.102735_bib2780","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0022-5347(05)66263-5","article-title":"Renal cell carcinoma in a transplanted kidney","volume":"165","author":"Mindrup","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2785","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1148\/radiol.11110122","article-title":"De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation","volume":"260","author":"Cornelis","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2790","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urology.2018.12.003","article-title":"Focal ablative therapy for renal cell carcinoma in transplant allograft kidneys","volume":"125","author":"Gul","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2795","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.12998\/wjcc.v7.i17.2487","article-title":"Systematic review of ablative therapy for the treatment of renal allograft neoplasms","volume":"7","author":"Favi","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.fjurol.2024.102735_bib2800","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1464-410X.2010.09856.x","article-title":"De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients","volume":"108","author":"Tsaur","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2805","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996\u20132009","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.fjurol.2024.102735_bib2810","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.19.02263","article-title":"Growth rates of genetically defined renal tumors: implications for active surveillance and intervention","volume":"38","author":"Ball","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2815","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/genes12020261","article-title":"Precision surgery and kidney cancer: knowledge of genetic alterations influences surgical management","volume":"12","author":"Gomella","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.fjurol.2024.102735_bib2820","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2825","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.fjurol.2024.102735_bib2830","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs. sunitinib in patients with met-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2835","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib2840","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00345-018-2307-6","article-title":"Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study)","volume":"36","author":"Nouhaud","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2845","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11255-019-02085-6","article-title":"Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification","volume":"51","author":"Boissier","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2850","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2214\/AJR.10.6330","article-title":"Evaluation of renal masses with contrast-enhanced ultrasound: initial experience","volume":"197","author":"Gerst","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2855","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/iju.13289","article-title":"Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: a prospective study","volume":"24","author":"Defortescu","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2860","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiol.2019182646","article-title":"Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment","volume":"292","author":"Silverman","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2865","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1148\/radiol.11111595","article-title":"The Bosniak renal cyst classification: 25 years later","volume":"262","author":"Bosniak","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2870","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1464-410X.2005.05442.x","article-title":"The Bosniak classification of renal cystic masses","volume":"95","author":"Warren","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2875","doi-asserted-by":"crossref","first-page":"e249007","DOI":"10.1148\/rycan.249007","article-title":"Differentiating benign from malignant cystic renal masses using CT texture-based machine learning algorithms","volume":"6","author":"Ramachandran","year":"2024","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib2880","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.juro.2016.09.160","article-title":"Bosniak classification for complex renal cysts reevaluated: a systematic review","volume":"198","author":"Schoots","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2885","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","article-title":"Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy","volume":"69","author":"Marconi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2890","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2019.07.017","article-title":"Long-term outcomes of patients with low grade cystic renal epithelial neoplasms","volume":"133","author":"Westerman","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2895","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2018.06.025","article-title":"Intraoperative cyst rupture during partial nephrectomy for cystic renal masses-does it increase the risk of recurrence?","volume":"200","author":"Pradere","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2900","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u00a0\u2013\u00a0part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2905","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2010.10.068","article-title":"Renal oncocytosis: management and clinical outcomes","volume":"185","author":"Adamy","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2910","first-page":"1257","article-title":"Renal hybrid oncocytic\/chromophobe tumors\u00a0\u2013\u00a0a review","volume":"28","author":"Hes","year":"2013","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2022.04.009","article-title":"Benefit and harm of active surveillance for biopsy-proven renal oncocytoma: a systematic review and pooled analysis","volume":"41","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib2920","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.urology.2021.05.034","article-title":"Active surveillance for biopsy proven renal oncocytomas: outcomes and feasibility","volume":"156","author":"Deledalle","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2925","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bju.13763","article-title":"Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis","volume":"119","author":"Patel","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2930","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2005.06.001","article-title":"Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy","volume":"66","author":"Neuzillet","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2935","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.juro.2011.05.080","article-title":"Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance","volume":"186","author":"Kawaguchi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2940","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1464-410X.2012.011136.x","article-title":"Renal oncocytoma growth rates before intervention","volume":"110","author":"Kurup","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2945","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.juro.2015.09.067","article-title":"Active surveillance for renal neoplasms with oncocytic features is safe","volume":"195","author":"Richard","year":"2016","journal-title":"J Urol"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.fjurol.2024.102735_bib2950","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13538","article-title":"Active surveillance is suitable for intermediate term follow-up of renal oncocytoma diagnosed by percutaneous core biopsy","volume":"118","author":"Liu","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.03.017","article-title":"Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up","volume":"55","author":"Alderman","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2960","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bju.15499","article-title":"Growth and renal function dynamics of renal oncocytomas in patients on active surveillance","volume":"128","author":"Neves","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib2965","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.urology.2021.05.034","article-title":"Active surveillance for biopsy proven renal oncocytomas: outcomes and feasibility","volume":"156","author":"Deledalle","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2970","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00345-020-03299-5","article-title":"Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma","volume":"39","author":"Meagher","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2975","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.urology.2017.09.016","article-title":"Comparative analysis of surgery, thermal ablation, and active surveillance for renal oncocytic neoplasms","volume":"112","author":"Miller","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102735_bib2980","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00125480-200007010-00007","article-title":"Benign tumors and tumor-like lesions of the adult kidney. Part II: benign mesenchymal and mixed neoplasms, and tumor-like lesions","volume":"7","author":"Tamboli","year":"2000","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2985","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2015.07.126","article-title":"Update on the diagnosis and management of renal angiomyolipoma","volume":"195","author":"Flum","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2990","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2214\/AJR.08.1180","article-title":"Angiomyolipoma with minimal fat on MDCT: can counts of negative-attenuation pixels aid diagnosis?","volume":"192","author":"Simpfendorfer","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102735_bib2995","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11934-013-0311-3","article-title":"Contemporary minimally invasive treatment options for renal angiomyolipomas","volume":"14","author":"Sivalingam","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib3000","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3005","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0022-5347(05)65160-9","article-title":"Etiology of spontaneous perirenal hemorrhage: a meta-analysis","volume":"167","author":"Zhang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.euo.2019.04.005","article-title":"Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel","volume":"3","author":"Fern\u00e1ndez-Pello","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-5347(17)46013-7","article-title":"The management of renal angiomyolipoma","volume":"135","author":"Oesterling","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bju.12604","article-title":"Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention","volume":"114","author":"Ouzaid","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2016.01.048","article-title":"Natural history of renal angiomyolipoma (AML): most patients with large AMLs>4cm can be offered active surveillance as an initial management strategy","volume":"70","author":"Bhatt","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.purol.2020.08.004","article-title":"[Results of active surveillance for sporadic renal angiomyolipomas greater than 4cm: a pledge for active surveillance]","volume":"31","author":"Grassano","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/PAS.0b013e318206f2a9","article-title":"Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification","volume":"35","author":"Nese","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3045","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-018-0870-y","article-title":"Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study","volume":"13","author":"Ebrahimi-Fakhari","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.fjurol.2024.102735_bib3055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3060","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3389\/fneur.2020.00972","article-title":"Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal angiomyolipomas","volume":"11","author":"Kingswood","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.annfar.2005.06.011","article-title":"[Prevention of venous thromboembolism in surgery and obstetrics]","volume":"24","author":"Samama","year":"2005","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.fjurol.2024.102735_bib3070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.eururo.2017.03.008","article-title":"Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis","volume":"73","author":"Tikkinen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/21681805.2023.2171112","article-title":"Incidence and associated risk factors of venous thromboembolism after open and laparoscopic partial nephrectomy in patients administered short-period thromboprophylaxis: a Danish nationwide population-based cohort study","volume":"57","author":"Azawi","year":"2023","journal-title":"Scand J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-024-04853-1","article-title":"Asymptomatic bacteriuria prior to partial and radical nephrectomy: to screen or not to screen? Results from the national and multicenter TOCUS database","volume":"42","author":"Ayoub","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1472-6963-13-202","article-title":"Effectiveness of nurse case management compared with usual care in cancer patients at a single medical center in Taiwan: a quasi-experimental study","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.fjurol.2024.102735_bib3090","doi-asserted-by":"crossref","first-page":"840363","DOI":"10.3389\/fonc.2022.840363","article-title":"Enhanced recovery after surgery protocol optimizes results and cost of laparoscopic radical nephrectomy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3095","doi-asserted-by":"crossref","first-page":"17201","DOI":"10.1038\/s41598-021-96676-y","article-title":"Postoperative outcomes of elderly patients undergoing partial nephrectomy","volume":"11","author":"Ingels","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib3100","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00345-018-2338-z","article-title":"Follow-up after curative treatment of localised renal cell carcinoma","volume":"36","author":"Dabestani","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3105","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00345-016-1796-4","article-title":"A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use","volume":"34","author":"Beisland","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clgc.2018.11.009","article-title":"Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival","volume":"17","author":"Merrill","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bju.16124","article-title":"Nephrectomy for kidney tumour increases the risk of de novo arterial hypertension","volume":"132","author":"Bigot","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2017020136","article-title":"Incident CKD after radical or partial nephrectomy","volume":"29","author":"Leppert","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.euf.2018.02.010","article-title":"Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis","volume":"5","author":"Dabestani","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib3130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eururo.2019.10.028","article-title":"Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the Eastern Cooperative Oncology Group\u00a0\u2013\u00a0American College of Radiology Imaging Network E2805 trial cohort","volume":"77","author":"Jamil","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0022-5347(05)00526-4","article-title":"Prognostic value of thrombocytosis in renal cell carcinoma","volume":"175","author":"Bensalah","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/s1677-5538.ibju.2019.0636","article-title":"Sarcopenia predicts prognosis of patients with renal cell carcinoma: a systematic review and meta-analysis","volume":"46","author":"Hu","year":"2020","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3145","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/01.ju.0000121440.82581.d3","article-title":"Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma","volume":"171","author":"Kim","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12894-020-00665-8","article-title":"Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis","volume":"20","author":"Shao","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euf.2021.02.009","article-title":"Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation","volume":"8","author":"Nocera","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102735_bib3160","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/PAS.0000000000000690","article-title":"Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution","volume":"40","author":"Khor","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3165","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3170","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bju.13669","article-title":"Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma","volume":"119","author":"Bailey","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3175","doi-asserted-by":"crossref","first-page":"427.e17","DOI":"10.1016\/j.urolonc.2015.04.011","article-title":"Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation","volume":"33","author":"Adibi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clgc.2014.12.001","article-title":"Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3185","doi-asserted-by":"crossref","first-page":"643065","DOI":"10.3389\/fonc.2021.643065","article-title":"Review of prognostic expression markers for clear cell renal cell carcinoma","volume":"11","author":"Petitprez","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3190","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.15673","article-title":"Risk models for recurrence and survival after kidney cancer: a systematic review","volume":"130","author":"Usher-Smith","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3195","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.19.00107","article-title":"Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation","volume":"37","author":"Correa","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euros.2021.09.004","article-title":"External validation of the ASSURE model for predicting oncological outcomes after resection of high-risk renal cell carcinoma (RESCUE study: UroCCR 88)","volume":"33","author":"Khene","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib3205","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41598-023-30826-2","article-title":"Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib3210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.euo.2022.07.007","article-title":"Application of machine learning models to predict recurrence after surgical resection of nonmetastatic renal cell carcinoma","volume":"6","author":"Khene","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41698-024-00532-x","article-title":"UroPredict: machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120)","volume":"8","author":"Margue","year":"2024","journal-title":"Npj Precis Onc"},{"key":"10.1016\/j.fjurol.2024.102735_bib3220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41698-024-00532-x","article-title":"UroPredict: Machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120)","volume":"8","author":"Margue","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.23517","article-title":"Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy","volume":"113","author":"Cindolo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3230","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/01.ju.0000096049.64863.a1","article-title":"Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population","volume":"170","author":"Han","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3235","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2004.09.104","article-title":"Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study","volume":"22","author":"Patard","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11934-007-0019-3","article-title":"Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma","volume":"8","author":"Tollefson","year":"2007","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.fjurol.2024.102735_bib3245","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s00345-019-02724-8","article-title":"Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy","volume":"37","author":"Gires","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1464-410X.2006.06616.x","article-title":"The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol","volume":"99","author":"Antonelli","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3255","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.juro.2016.02.068","article-title":"The usefulness of chest X-rays for T1a renal cell carcinoma surveillance","volume":"196","author":"Canvasser","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3260","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jacr.2014.01.023","article-title":"ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma","volume":"11","author":"Casalino","year":"2014","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3265","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2018.05.002","article-title":"Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis","volume":"74","author":"Sun","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3270","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.eururo.2020.12.029","article-title":"Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial","volume":"79","author":"Motzer","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3280","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3285","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3290","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/KCA-180049","article-title":"Everolimus exposure as a predictor of toxicity in renal cell cancer patients in the adjuvant setting: results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249)","volume":"3","author":"Synold","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3300","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3305","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma, reply","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3310","first-page":"1133","article-title":"Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"23","author":"Choueiri","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3315","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.fjurol.2024.102735_bib3320","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3325","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3330","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3335","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3340","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3345","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3350","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3355","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3360","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.25","article-title":"First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC","volume":"110","author":"Ko","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3365","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3370","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3375","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3385","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of Immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3390","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3395","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3400","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3405","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3410","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3415","doi-asserted-by":"crossref","first-page":"108720","DOI":"10.1016\/j.intimp.2022.108720","article-title":"The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis","volume":"108","author":"Mori","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3420","doi-asserted-by":"crossref","first-page":"604.e9","DOI":"10.1016\/j.urolonc.2020.02.029","article-title":"Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database","volume":"38","author":"Singla","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3425","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3430","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/JS9.0000000000000314","article-title":"The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis","volume":"109","author":"Chen","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.fjurol.2024.102735_bib3435","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JU.0000000000002495","article-title":"The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a real-world multi-institutional analysis","volume":"208","author":"Ghatalia","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3440","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.eururo.2019.12.018","article-title":"Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge?","volume":"77","author":"Pignot","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3445","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.urolonc.2019.08.012","article-title":"Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma","volume":"37","author":"Singla","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euros.2023.01.016","article-title":"Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals","volume":"50","author":"Shapiro","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102735_bib3455","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.euo.2023.03.003","article-title":"Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy: a multicenter collaborative study","volume":"6","author":"Yip","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3460","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euo.2022.07.002","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3465","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2020.05.014","article-title":"Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines","volume":"78","author":"Larcher","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3470","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3475","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2018.09.016","article-title":"Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma","volume":"75","author":"Bhindi","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3480","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11523-024-01065-w","article-title":"Real-world impact of upfront cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma treated with first-line immunotherapy combinations or tyrosine kinase inhibitors (a sub-analysis from the ARON-1 retrospective study)","volume":"19","author":"Fiala","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3485","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3490","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3495","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.juro.2016.07.079","article-title":"Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"197","author":"Zaid","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3500","doi-asserted-by":"crossref","first-page":"943604","DOI":"10.3389\/fsurg.2022.943604","article-title":"Role of metastasectomy in the management of renal cell carcinoma","volume":"9","author":"Mikhail","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.fjurol.2024.102735_bib3505","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3332\/ecancer.2019.967","article-title":"Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model","volume":"13","author":"Fares","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.fjurol.2024.102735_bib3510","doi-asserted-by":"crossref","first-page":"592243","DOI":"10.3389\/fonc.2020.592243","article-title":"Nomogram predicting survival to assist decision-making of metastasectomy in patients with metastatic renal cell carcinoma","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3515","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JU.0000000000000488","article-title":"Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era","volume":"203","author":"Lyon","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3520","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.urolonc.2021.02.026","article-title":"The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"39","author":"Hsieh","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3525","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-023-04706-3","article-title":"Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review","volume":"42","author":"Tayeh","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3530","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00345-022-03960-1","article-title":"Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies","volume":"40","author":"St\u00fchler","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3535","doi-asserted-by":"crossref","first-page":"799.e1","DOI":"10.1016\/j.urolonc.2020.07.021","article-title":"Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian Kidney Cancer information system experience","volume":"38","author":"Dragomir","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3540","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clgc.2022.03.013","article-title":"Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: analysis of the REMARCC registry","volume":"20","author":"Meagher","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3545","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.euo.2022.11.003","article-title":"International multi-institutional characterization of the perioperative morbidity of metastasectomy for renal cell carcinoma","volume":"6","author":"Lyon","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3550","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102735_bib3555","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102735_bib3560","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3565","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.juro.2018.08.049","article-title":"Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma","volume":"201","author":"Franzese","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3570","doi-asserted-by":"crossref","first-page":"103242","DOI":"10.1016\/j.critrevonc.2021.103242","article-title":"Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: a systematic review","volume":"159","author":"Ingrosso","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3575","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1007\/s00345-021-03742-1","article-title":"Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy","volume":"39","author":"Liu","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3580","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3585","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3590","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3595","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3600","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic Radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma\u00a0\u2013\u00a0the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3605","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3171\/2018.8.JNS182100","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"132","author":"Juloori","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.fjurol.2024.102735_bib3610","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00066-010-2055-z","article-title":"Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients","volume":"186","author":"Fokas","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3615","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","article-title":"Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report","volume":"27","author":"Langrand-Escure","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.fjurol.2024.102735_bib3620","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clgc.2019.02.007","article-title":"Stereotactic radiation therapy for renal cell carcinoma brain metastases in the tyrosine kinase inhibitors era: outcomes of 120 patients","volume":"17","author":"Klausner","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3625","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5489\/cuaj.6963","article-title":"Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"15","author":"Peng","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.fjurol.2024.102735_bib3630","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdv037","article-title":"Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases","volume":"26","author":"de Ba\u00e8re","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3635","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1245\/s10434-009-0664-5","article-title":"Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma","volume":"16","author":"Shu Yan Huo","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3640","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1464-410X.2009.08459.x","article-title":"Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma","volume":"104","author":"Soga","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102735_bib3645","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1148\/radiol.2015142029","article-title":"Unresectable adrenal metastases: clinical outcomes of radiofrequency ablation","volume":"277","author":"Hasegawa","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2024.102735_bib3650","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1186\/s12885-019-6345-2","article-title":"Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience","volume":"19","author":"Gonnet","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3655","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.juro.2014.03.006","article-title":"Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma","volume":"192","author":"Welch","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3660","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3665","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.fjurol.2024.102735_bib3670","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.363","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs. sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3675","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3680","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3685","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib (N+C) vs. sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial","volume":"23","author":"Bourlon","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3690","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3695","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102735_bib3700","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3705","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3710","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.22.01414","article-title":"Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"41","author":"Su\u00e1rez","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3715","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs. sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3720","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2024.102735_bib3725","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3730","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.02.001","article-title":"Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial","volume":"129","author":"Negrier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3735","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3740","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3745","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)\u2020","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3750","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3755","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3760","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3765","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.juro.2007.01.063","article-title":"Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d\u2019\u00c9tudes des Tumeurs Uro-G\u00e9nitales) study","volume":"177","author":"Oudard","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.04.007","article-title":"Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: a prospective, multicentre, single-arm, phase 2 study","volume":"100","author":"Sheng","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.fjurol.2024.102735_bib3775","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 study)","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.fjurol.2024.102735_bib3780","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.03.018","article-title":"Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: results of a prospective phase II trial (BEVABEL-GETUG\/AFU24)","volume":"186","author":"Thibault","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302400192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302400192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:03:32Z","timestamp":1732248212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295039302400192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":557,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S295039302400192X"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102735","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Management of kidney cancer","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102735"}}